Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate

被引:9
作者
Yang, Yongsheng [1 ]
Mohammad, Adil [1 ]
Berendt, Robert T. [2 ]
Carlin, Alan [1 ]
Khan, Mansoor A. [1 ]
Faustino, Patrick J. [1 ]
机构
[1] US FDA, Div Prod Qual Res, Off Pharmaceut Qual, Life Sci Bldg 64, Silver Spring, MD 20993 USA
[2] US FDA, Off Lifecycle Drug Prod, Off Pharmaceut Qual, Life Sci Bldg 75, Silver Spring, MD 20993 USA
关键词
sevelamer; inductively coupled plasma; phosphate binding; langmuir equation; bioequivalence; polymeric drugs; kinetics; absorption; drug interaction; CHRONIC-RENAL-FAILURE; PHOSPHATE BINDERS; CALCIUM-CARBONATE; HYPERPHOSPHATEMIA; SAFETY; MEAL; PHOSPHORUS; METABOLISM; ABSORPTION; MORTALITY;
D O I
10.1002/jps.24572
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The objective of this project is to develop an in vitro approach that can be used to determine the phosphate binding capacity of sevelamer hydrochloride and carbonate for both drug products and active pharmaceutical ingredients (APIs). A simple and efficient inductively coupled plasma spectrometer method for analysis of phosphate at physiologically relevant pH conditions has been developed and validated. The method addresses each of the analytical validation characteristics such as linearity, accuracy, precision, stability, and selectivity, and meets the acceptance criteria defined in the United States Food and Drug Administration guidance (Food and Drug Administration, Center for Drug Evaluation and Research. 2001. Guidance for industry-Bioanalytical method validation, May). The in vitro phosphate binding efficacies were systematically evaluated and compared for two drug products and two APIs. The phosphate binding profiles appeared similar between the drug products. Under all conditions, the sevelamer-phosphate binding reached equilibrium at 6 h. The 90% confidence interval for the k(2) ratio (sevelamer carbonate vs. sevelamer hydrochloride) was well within 80%-125% under all pH conditions. However, the k(1) ratio varied, indicating that there exists difference in the binding affinity. Our findings will be useful in assisting with "in vivo" biowaiver for the approval of generic sevelamer drug products. (C) 2016 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:864 / 875
页数:12
相关论文
共 32 条
[1]   DIALYSIS ENCEPHALOPATHY SYNDROME - POSSIBLE ALUMINUM INTOXICATION [J].
ALFREY, AC ;
LEGENDRE, GR ;
KAEHNY, WD .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (04) :184-188
[2]  
Bellasi Antonio, 2006, Hemodial Int, V10, P225, DOI 10.1111/j.1542-4758.2006.00100.x
[3]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[4]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[5]  
Braun J, 2004, CLIN NEPHROL, V62, P104
[6]   Bile acid binding to sevelamer HCl [J].
Braunlin, W ;
Zhorov, E ;
Guo, A ;
Apruzzese, W ;
Xu, QW ;
Hook, P ;
Smisek, DL ;
Mandeville, WH ;
Holmes-Farley, SR .
KIDNEY INTERNATIONAL, 2002, 62 (02) :611-619
[7]   Control of hyperphosphatemia among patients with ESRD [J].
Coladonato, JA .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 :S107-S114
[8]  
DAVIS GR, 1983, GASTROENTEROLOGY, V85, P908
[9]   Drug, meal and formulation interactions influencing drug absorption after oral administration - Clinical implications [J].
Fleisher, D ;
Li, C ;
Zhou, Y ;
Pao, LH ;
Karim, A .
CLINICAL PHARMACOKINETICS, 1999, 36 (03) :233-254
[10]   FREUNDLICH AND LANGMUIR ISOTHERMS AS MODELS FOR THE ADSORPTION OF TOXICANTS ON ACTIVATED-CHARCOAL [J].
GESSNER, PK ;
HASAN, MM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1987, 76 (04) :319-327